In the last lipoprotein (a) master class In class, we introduced the three major pathogenic components and pathophysiological mechanisms of lipoprotein(a) in detail.
We are honored to invite the Chinese Medical Association Cardiovascular Branch of Metabolic Member of the Cardiovascular Disease Group, member of the Standing Committee of the Heart Failure Professional Committee of the Chinese Medical Doctor Association, and Director of the Intracardial District Three of the Guangdong Provincial People’s Hospital and the Guangdong Provincial Institute of Cardiovascular Diseases The application of lipoprotein(a) elevation is described in detail for the reader.
Summary of key points:
ღ reverse Sense oligonucleotidesare chemically synthesized single-stranded nucleotide molecules that precisely bind to the targetmRNA through the principle of complementary base pairing to prevent the production of pathogenic proteins; span>Pelacarsen targeting Apo(a) and Mipomesen targeting ApoB have been developed.antisense oligonucleotidesdrugs can reduce < /span>Lp(a) level, but Mipomexane is not approved by the European Medicines Agency.
(see the video below: 00:00-06:30)ღ The latest foreign guidelines / consensus pointed out that antisense oligonucleotidescan reduceLp(a) production, thereby Decrease Lp(a) levels. (See the video below: 06:31-08:54)
ღ has been The completed phase II study showed that Pelacarsen can reduce Lp(a) levels by 50%-80%, and the overall safety is good.
(see the video below: 08:55-22:23)
ღ The ongoing global large-scalePhase III clinical trial-HORIZON study will further verify the cardiovascular benefits of Lp(a) intervention by Pelacarsen.
(see the video below: 22:24-27:58)
Professor Li Liwen
< p>•MD, Chief Physician, Master Supervisor, Adjunct Professor of Southern Medical University, Administrative Director of Guangdong Provincial People’s Hospital and Guangdong Provincial Institute of Cardiovascular Diseases, FACC, FESC.
•Member of the Metabolic Cardiovascular Disease Group of the Cardiovascular Branch of the Chinese Medical Association, member of the Standing Committee of the Heart Failure Professional Committee of the Chinese Medical Doctor Association, and a cardiovascular physician of the Chinese Medical Doctor Association Member of the Heart Failure Study Group of the branch, member of the Standing Committee of the Heart Failure Specialized Committee of the National Cardiology Expert Committee, Deputy Head of the Heart Failure Study Group of the Cardiovascular Disease Branch of the Guangdong Medical Association, and Specialist in Heart Failure and Metabolic Cardiovascular Diseases of the Guangdong Women’s Physician Association Committee Chairman.
• “Chinese Journal of Cardiovascular and Cerebrovascular Diseases in the Elderly”, “Chinese Journal of Cardiovascular Diseases (Online Edition)”, “Chinese Journal of Cardiovascular and Cerebrovascular Diseases” He is an editorial board member of the Journal of Heart Failure and Cardiomyopathy, and a reviewer of the Chinese Journal of Cardiovascular Disease and Lingnan Journal of Cardiovascular Disease.
Review of Past Issues
☞ Lipoprotein (a) Master Class 1｜New horizons of lipid-lowering therapy, Professor Yuan Zuyi discusses the clinical significance of lipoprotein(a) in detail
☞ Lipoprotein(a) Master Class 2 ｜Professor Peng Daoquan: The pathophysiological mechanism of the causal relationship between lipoprotein(a) and CVD
☞ Lipoprotein(a) Master Class No.3｜Professor Wu Pingsheng: Lipoprotein(a) Evidence-based evidence on the causal relationship between protein(a) and CVD
☞ Lipoprotein(a) Master Class No. 4｜Professor Li Jianjun: Lipoprotein(a) ) and CVD in Chinese population research evidence
☞ Small lipoprotein(a) master class No. 5｜Professor Yuan Hui: Current status and thinking of clinical testing of lipoprotein(a)
☞ Lipoprotein(a) Master Class No.6｜Professor Zhu Ye: Treatment of Elevated Lipoprotein(a)
☞ Lipoprotein Small (a) Master Class No.7｜Professor Chen Zhenyue: The latest progress of lipoprotein(a) and related guidelines/consensus interpretation
☞ Lipoprotein(a) Master Class No. 8｜Professor Sun Yihong: Interpretation of expert scientific advice on the relationship between lipoprotein(a) and cardiovascular risk and clinical management (Part 1)
☞ Lipoprotein(a) ) Master Class No. 9｜Professor Guo Yuanlin: Interpretation of expert scientific advice on the relationship between lipoprotein(a) and cardiovascular risk and clinical management (Part 2)
☞ Lipoprotein Small (a) Master Class No. 10｜Professor Wu Naqiong: Starting from Lp(a), exploring new strategies for CAVS management
☞ < /span>Lipoprotein Small(a) Master Class No.11｜Professor Liu Meilin: New Progress in Lp(a) Research
☞ Lipo Small Protein(a) Master Class No. 12｜Professor Liu Liping: The causal relationship between Lp(a) and stroke☞ Lipoprotein(a) Master Class No. 13｜ Prof. Wu Pingsheng: Pathophysiological Mechanisms of Lipoprotein(a)